source
- Novo Nordisk aims to bring triple-G obesity injection to market by 2030Novo Nordisk said it plans to launch a triple‑G obesity injection by 2030. The drug would combine agonist activity at the GLP‑1, GIP and glucagon receptors, a class that researchers believe could b…
- Logistics firms tackle time-critical delivery of radiopharmaceuticals for cancer careRadiopharmaceuticals are emerging as a key tool in oncology, offering cell‑level targeting that spares healthy tissue while delivering radiation directly to tumors. Because the radioactive isotope…